A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
← catalyst calendarSponsored by Esperion Therapeutics, Inc. (industry) · ESPR — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
31actual
Sites
24
Countries
Canada, Denmark, Germany +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-12 | actual | When the study began enrolling |
| Primary completion | 2025-06-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-04 | actual | The whole study's end, after follow-up |
| First posted | 2023-01-23 | actual | When this record first appeared on the registry |
| Results posted | 2026-07-17 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hypercholesterolemia
Intervention
- Drug: Bempedoic acid — also filed as ETC-1002
Primary outcomes
what the primary-completion date above is the date OFObserved Trough Plasma Concentration of ETC-1002 Following 8 Weeks of Steady State Dosing of Bempedoic Acid
measured Week 8 pre-dose
Model-based Steady State Area Under the Concentration-time Curve Over 24 Hours (AUC,24ss) of ETC-1002
measured 24 hours
Model-based Steady State Average Plasma Concentration (Cavg,ss) of ETC-1002
measured Week 8, 24 hours post-dose at steady state
Model-based Steady State Maximum Plasma Concentration (Cmax,ss) of ETC-1002
measured Day 1: 1-hour and 4 hours post-dose; Week 4 pre-dose; Week 8 pre-dose
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2025-01-29 · 709 KB · Prot_000.pdf
Statistical Analysis Planposted 2025-06-06 · 2.5 MB · SAP_001.pdf
Permalink · ESPR's whole pipeline · Catalyst calendar · Every registered study · What changed